ADCs : antibodies and cytotoxic molecules united against tumours
From Paul Ehrlich’s early “magic bullet” concept to today’s approved therapeutics, Antibody-Drug Conjugates (ADCs) represent a major breakthrough in targeted cancer therapy. By combining the selectivity of monoclonal antibodies with the potency of cytotoxic agents, ADCs aim to eliminate tumor cells while sparing healthy tissues. This article dives into the evolution, design strategies, and key challenges of these complex biologics.
breast cancer
The MabDesign market analysis for this month of pink October gives you an overview of market dynamics and projects in development targeting the treatment of breast cancer.
Multiple Sclerosis
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting the treatment of multiple sclerosis.
The immuno-oncology market
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
Glioblastoma
This month’s MabDesign market analysis gives you an overview of market dynamics and pipeline projects targeting the glioblastoma.
Therapeutic vaccines in oncology
This month, MabDesign’s market analysis provides an overview of the market for therapeutic oncology vaccines.